NUGALVIQ
Live / Applied — Non-final action mailed (as of 11 Feb 2026)
What this means for you
Not registered yet, but its 18 Sept 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99400186
- Mark type
- Design + words
- Filed
- 18 Sept 2025
- Attorney of record
- Anna Kurian Shaw
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for treatment of rare orphan diseases; Pharmaceutical preparations for treatment of diseases that impact sugar and glucose metabolism; Pharmaceutical preparations for inhibiting aldose reductase; Pharmaceutical preparations for treatment of galactosemia, sorbitol dehydrogenase (SORD) deficiency and PMM2-congenital disorder of glycosylation (PMM2-CDG)
Owner
- Applied Therapeutics, Inc., New York, NY, US
Prosecution history
- 11 Feb 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 11 Feb 2026 — NON-FINAL ACTION E-MAILED
- 11 Feb 2026 — NON-FINAL ACTION WRITTEN
- 11 Feb 2026 — ASSIGNED TO EXAMINER
- 10 Feb 2026 — NOTICE OF DESIGN SEARCH CODE E-MAILED
- 10 Feb 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 18 Sept 2025 — APPLICATION FILING RECEIPT MAILED
- 18 Sept 2025 — NEW APPLICATION ENTERED